Scryb Inc. Forum: Community User: Philipp85

super news es wird noch zum Miliarden geschäft.

Sehr gut, so kann es weiter gehen

Hört sich sehr geplant an...wird uns n. m. M. noch sehr Freude machen...abwarten.

anuary 03, 2018 – ChroMedX Corp. (the “Company”) (CSE: CHX, OTC: CHXIF, Frankfurt: EIY2), developer of the HemoPalm Handheld Blood Analyzer System, is pleased to report on the signing of a definitive agreement with diagnostic marketing experts DxEconomix Inc. (DxEx) to conduct a high value transaction for the Company.   In August 2017 ChroMedX retained the consulting company for an evaluation of the HemoPalm Analyzer’s product viability, value offering, and market potential. Following an initial 90-day due diligence term ChroMedX accepted a proposal from DxEx and entered into a binding Letter-of-Intent stipulating a 60-day period for the companies to form and execute a definitive agreement. The definitive agreement has now been finalized and signed by both parties.

Ja nur weil einige billig einsteigen wollten! Aber die bringen demnächst bestimmt eine Klarstellung bzgl. BaFin und FDA-Zulassung

ja wir wären jetzt bestimmt bei 1 Euro, aber es wird wieder.

Danke lumino

Hallo zusammen, ich habe Antwort wegen BaFin und der FDA-Zulassung bekommen. Siehe unten. Hi, Apologies for not responding to you earlier. We must have missed the facebook notification over the holidays. In regards to your first question about the FDA process. HemoPalm will be class II device just like iStat and Epocal devices currently on the market and will follow the same approval process. This approval process (FDA 510(k )) basically requires proof that the device substantially equivalent to a legally marketed device that is not subject to Premarket approvals. Applicants must compare their device to one or more similar legally marketed devices and make and support their substantially equivalent claims. If the device is substantially equivalent to an approved medical device, it is placed in the same class. If it is not substantially equivalent, it becomes non-SE and is placed into Class III. Members of the ChroMedX development team have done several successful FDA 510(k ) applications before including a handheld blood analyzer very similar in core-functionality to the HemoPalm. The US FDA is by far the most important approval as it is the largest market but the technology will also require Health Canada and CE approvals for sale in Canada and Europe. The FDA process starts once the pre-production device is complete. In regards to your second question about the BaFin warning. The Company is aware of this and ChroMedX council in Frankfurt are working with BaFin now to investigate what the issue was. This is a warning in regards to coverage of ChroMedX being potentially misleading NOT information issued by the Company. ChroMedX disseminates its news only through accredited dissemination and translation services. Our news is always posted and available on our website and eblasted in a timely fashion in accordance with standard regulatory practices. If you are concerned about anything you read or have questions please email investor relations at info@chromedx.com Thanks,

Ja glaube ich auch :) Es müssten bald News kommen!

Hemopalm wird sich durchsetzen und dann sehen wir hier ganz andere Kurse!

Handelsvolumen besser als die letzten paar Wochen

Zieht an!

Aus dem hause pollinger?

https://www.wallstreet-online.de/nachricht/10165939-best-of-2017-aktien-aktien-kaufen KAUFEN: CHROMEDX CORP. (WKN: A12B6G) Vom Pennystock zum Superstar der Branche – diese Reise hat bei ChroMedX erst begonnen – JETZT, in den letzten Wochen! Warum diese Aktie für mich immer noch ein Kauf ist, erfahren Sie in meinem letzten Blogbeitrag: Die beste Aktie, die Sie heuer noch kaufen können. Zwei echte Fachexperten Experten machen sensationelle Aussagen über die Technologie! Dr. Thomas Schumpberger: „Eine echte Revolution! Wir haben gleich erkannt, dass wir es hier mit einem POCT-Blutgasanalysegerät der nächsten oder dritten Generation zu tun haben…” ...

In Kanada plus 10,71%

Wird erst bei News wieder in Bewegung kommen (Zulassung etc.)...bin gespannt